Transtarget Inc
Multifunctional antibody therapeutic targeting ischemic myocardium to reduce cell death and promote cardiac regeneration after acute myocardial infarction
- Sector
- Biotech
- Total capital
- $674K
- Federal grants
- $674K
- 3 awards · 2016–2018
- Rank in peer group#315 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2025
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Multifunctional Antibody Therapy for Acute Myocardial Infarction$225K
- Federal grantHealth and Human S · Phase I · Multifunctional Antibody Therapy for Acute Myocardial Infarction$225K
- Federal grantHealth and Human S · Phase I · Novel Stem Cell Therapy for Acute Myocardial Infarction in Diabetes Mellitus$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#70 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 6- GrantedMethods And Compositions For Vaccinating And Boosting Cancer PatientsUSPTOUS 12,324,836
- PendingBispecific AntibodiesUSPTOApplication 63273805
- PendingMethods And Compositions For Vaccinating And Boosting Cancer PatientsUSPTOApplication PCTUS2017065177
Show all 6 patent records
- Methods And Compositions For Vaccinating And Boosting Cancer PatientsJun 10, 2025 · US 12,324,836Granted
- Bispecific AntibodiesApplication 63273805Pending
- Methods And Compositions For Vaccinating And Boosting Cancer PatientsApplication PCTUS2017065177Pending
- Compositions And Methods For Tissue RepairApplication PCTUS2008065303Pending
- Method For Producing A Population Of Homogenous Tetravalent Bispecific AntibodiesApplication PCTUS2006040029Pending
- Improved Bispecific AntibodiesApplication PCTUS2005023242Pending
Related companies, and why
- Nuvectis Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- ImmuneBridge Inc.Similar federal contract value in Biotech · null in contracts
- IpiNovyx Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Lang Artificial Intelligence, Inc.Similar federal contract value in Biotech · null in contracts
- STEMLINE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- Form BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .